Screener
ANI Pharmaceuticals ANIP Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's accounts receivable?
- ANI Pharmaceuticals (ANIP) reported accounts receivable of $274.47M in Q2 2026.
- How has ANI Pharmaceuticals's accounts receivable changed year-over-year?
- ANI Pharmaceuticals's accounts receivable increased by 21.6% year-over-year, from $225.65M to $274.47M.
- What is the long-term trend for ANI Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accounts receivable has grown at a 24.0% compound annual growth rate (CAGR), from $95.79M to $281.08M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about ANI Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude